Menstrual Disorders Practice Questions

Q: Secondary amenorrhea is defined as:

Absence of menstruation for three normal menstrual cycles.. **Explanation:** Secondary amenorrhea is defined as the cessation of menstruation in a woman who has previously established a regular menstrual pattern. The standard clinical criteria for diagnosis are: 1. Absence of menses for **3 months** (3 cycles) in a woman with previously regular cycles. 2. Absence of menses for **6 months** in a woman with previously irregular cycles. **Analysis of Options:** * **Option B (Correct):** This aligns with the standard diagnostic criteria for women with regular cycles. It represents a sufficient duration to warrant clinical investigation for underlying pathology (e.g., PCOS, pregnancy, or hyperprolactinemia). * **Option A:** Missing one cycle is common due to transient stress or illness and is not clinically classified as amenorrhea. * **Option C:** While 6 months is the criteria for women with *irregular* cycles, the standard textbook definition for secondary amenorrhea (unless specified otherwise) typically highlights the 3-month threshold for regular cycles. * **Option D:** One year is the duration required to diagnose **menopause**, not secondary amenorrhea. **NEET-PG High-Yield Pearls:** * **Most Common Cause:** The most common cause of secondary amenorrhea is **pregnancy**; this must always be ruled out first with a UPT. * **Most Common Pathological Cause:** Polycystic Ovary Syndrome (PCOS). * **Asherman Syndrome:** The most common cause of secondary amenorrhea following a D&C (uterine synechiae). * **Progesterone Challenge Test:** Used to assess endogenous estrogen levels and outflow tract patency. Withdrawal bleeding indicates an intact HPO axis and adequate estrogen.

Q: What is the most common endometrial pattern in dysfunctional uterine bleeding?

Normal. **Explanation:** Dysfunctional Uterine Bleeding (DUB) is defined as abnormal uterine bleeding in the absence of any detectable organic pelvic pathology, systemic disease, or pregnancy. **1. Why "Normal" is correct:** In the majority of cases, particularly in women of reproductive age, the endometrial histology in DUB is found to be **normal (proliferative or secretory)**. This occurs because the bleeding is often due to transient hormonal imbalances or local vascular dysregulation rather than a persistent structural change in the endometrium. While DUB is a diagnosis of exclusion, statistical data and clinical studies confirm that a "normal" endometrial pattern is the most frequent finding upon biopsy. **2. Analysis of Incorrect Options:** * **Hyperplastic (Swiss-Cheese pattern):** This is characteristic of cystic glandular hyperplasia, typically seen in **metropathia haemorrhagica** (a specific type of anovulatory DUB). While high-yield for exams, it is not the *most* common overall pattern. * **Nonsecretory (Proliferative):** This indicates anovulatory cycles. While common in extremes of reproductive life (puberty and perimenopause), it ranks second to a normal pattern across the general population. * **Atrophic:** This is the most common cause of postmenopausal bleeding, but it is a less common finding in DUB during the reproductive years. **Clinical Pearls for NEET-PG:** * **Most common cause of DUB:** Anovulation (approx. 80% of cases). * **Metropathia Haemorrhagica (Schroeder’s Disease):** Characterized by specialized "Swiss-cheese" hyperplasia, usually occurring in perimenopausal women due to persistent estrogen stimulation without progesterone. * **Gold Standard Investigation:** For women >35 years with DUB, **Fractional Curettage or Endometrial Biopsy** is mandatory to rule out endometrial carcinoma.

Q: Which of the following is NOT a treatment for dysfunctional uterine bleeding?

Ovariotomy. **Explanation:** Dysfunctional Uterine Bleeding (DUB), now more commonly classified under the **PALM-COEIN** criteria as AUB-E (Endometrial) or AUB-O (Ovulatory dysfunction), is primarily a hormonal imbalance resulting in abnormal shedding of the endometrium. **Why Ovariotomy is the Correct Answer:** Ovariotomy refers to the surgical removal of an ovary. This is **not** a treatment for DUB because DUB is a functional disorder of the uterine lining, not a primary surgical disease of the ovaries. Removing the ovaries would induce premature menopause and does not address the underlying endometrial instability. Surgical management for DUB, when medical therapy fails, typically involves endometrial ablation or hysterectomy, not ovariotomy. **Analysis of Incorrect Options:** * **Oral Contraceptive Pills (OCPs):** These are first-line treatments. They regulate the cycle, provide progestational support to stabilize the endometrium, and induce withdrawal bleeds. * **Estrogen:** High-dose estrogen is used in acute, heavy bleeding episodes to promote rapid "re-epithelialization" of the denuded endometrial surface, effectively stopping the hemorrhage. * **Progesterone:** Often considered the "medical curette," progestins (like Medroxyprogesterone acetate or Norethisterone) are used to treat DUB by counteracting estrogen-induced hyperplasia and ensuring organized shedding. **High-Yield Clinical Pearls for NEET-PG:** * **DOC for DUB:** In most stable cases, **NSAIDs or Tranexamic acid** are used for symptom relief, but **OCPs/Levonorgestrel-IUD (Mirena)** are the gold standard for long-term medical management. * **Mirena (LNG-IUD):** Currently considered the most effective medical treatment for heavy menstrual bleeding, often superior to oral medications. * **Aged >35 years:** Always perform an endometrial biopsy to rule out endometrial hyperplasia or malignancy before starting hormonal therapy for DUB.

Q: Which of the following is false regarding Mittelschmerz?

Treatment is with estrogen. **Explanation:** **Mittelschmerz** (German for "middle pain") refers to mid-cycle ovulatory pain. The correct answer is **A** because the treatment for Mittelschmerz is **not** estrogen; rather, it is managed with reassurance, analgesics (NSAIDs), or **Combined Oral Contraceptive Pills (COCPs)** if the pain is recurrent and severe. COCPs work by suppressing ovulation, which is the underlying cause of the pain. **Analysis of Options:** * **Option B (Duration):** This is a true statement. The pain typically lasts from a few minutes to a few hours and rarely exceeds 12–24 hours. * **Option C (Spotting):** This is true. The sudden drop in estrogen levels just before ovulation can cause slight endometrial shedding, leading to mid-cycle "spotting." * **Option D (Timing):** This is true. In a typical 28-day cycle, ovulation occurs around day 14. The pain coincides with the rupture of the Graafian follicle. **Pathophysiology & Clinical Pearls:** The pain is attributed to the rapid expansion of the dominant follicle or the irritation of the pelvic peritoneum by follicular fluid and blood released during ovulation. **High-Yield Facts for NEET-PG:** 1. **Diagnosis:** It is a diagnosis of exclusion. One must rule out appendicitis, ectopic pregnancy, and PID. 2. **Lateralization:** The pain is typically unilateral and switches sides from month to month depending on which ovary is ovulating. 3. **Key Feature:** It is a physiological condition, not a pathological one. 4. **Management:** Reassurance is the first line of management. For severe cases, **ovulation suppression** (via COCPs) is the definitive medical approach.

Q: In dysfunctional uterine bleeding (DUB), what is the typical hormonal imbalance?

Increased estrogen. **Explanation:** **Dysfunctional Uterine Bleeding (DUB)**, now classified under the PALM-COEIN system as AUB-O (Ovulatory dysfunction), most commonly results from **anovulation**. **Why "Increased Estrogen" is correct:** In an anovulatory cycle, the failure of ovulation means no corpus luteum is formed. Consequently, there is no production of **progesterone**. This leads to a state of **"unopposed estrogen"** action on the endometrium. The estrogen causes continuous proliferation of the endometrial lining without the stabilizing effect of progesterone. Eventually, the endometrium outgrows its blood supply, leading to asynchronous breakdown and heavy, irregular bleeding (estrogen breakthrough bleeding). **Analysis of Incorrect Options:** * **B & C (Receptor Imbalance):** DUB is primarily a hormonal signaling issue rather than a primary pathology of the estrogen or progesterone receptors themselves. While receptor sensitivity can vary, the hallmark of the condition is the systemic lack of progesterone. * **D (Pituitary hormone imbalance):** While the hypothalamus-pituitary-ovarian (HPO) axis is disrupted, the term "pituitary hormone imbalance" is too vague. The specific clinical manifestation of DUB is driven by the local effect of estrogen on the uterus. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of DUB:** Anovulation (especially at extremes of reproductive age—puberty and perimenopause). * **Endometrial Histology:** Typically shows **proliferative phase** or endometrial hyperplasia due to unopposed estrogen. * **Drug of Choice:** For acute bleeding, high-dose estrogen or OCPs; for long-term management of anovulatory DUB, **Progestogens** (to stabilize the lining) or **Levonorgestrel-IUS (Mirena)** are preferred. * **Gold Standard Investigation:** Transvaginal Ultrasound (TVS) to assess endometrial thickness; Endometrial biopsy is mandatory if age >35–45 years to rule out malignancy.

Q: A patient presents with a history of frequent cycles accompanied by heavy bleeding. What is this condition called?

Polymenorrhagia. This question tests your understanding of the terminology used to describe abnormal uterine bleeding (AUB). To arrive at the correct answer, you must break down the clinical presentation into its two components: **frequency** and **volume**. ### 1. Why Polymenorrhagia is Correct The patient presents with two distinct issues: * **Frequent cycles:** A cycle length of less than 21 days is termed **Polymenorrhea**. * **Heavy bleeding:** Excessive blood loss (>80 ml) or prolonged duration (>7 days) during a regular cycle is termed **Menorrhagia**. When these two conditions coexist—meaning the patient bleeds too often and too much—the combined term is **Polymenorrhagia** (also known as Epimenorrhagia). ### 2. Analysis of Incorrect Options * **A. Menorrhagia:** This refers only to heavy or prolonged bleeding occurring at regular intervals (21–35 days). It does not account for the increased frequency mentioned in the stem. * **B. Polymenorrhea:** This refers only to the increased frequency of cycles (cycles <21 days). The flow itself may be normal in amount and duration. * **D. Metrorrhagia:** This refers to irregular, acyclic bleeding occurring between expected menstrual periods (intermenstrual bleeding). ### 3. NEET-PG High-Yield Pearls * **Normal Menstrual Parameters:** Cycle length: 21–35 days; Duration: 2–7 days; Blood loss: 20–80 ml. * **Oligomenorrhea:** Infrequent cycles occurring at intervals >35 days. * **Hypomenorrhea:** Scanty flow or decreased duration (<2 days) at regular intervals. * **FIGO Classification (PALM-COEIN):** Modern clinical practice is moving away from these traditional terms toward the PALM-COEIN system, which classifies AUB by etiology (e.g., Polyp, Adenomyosis, Leiomyoma, Malignancy, etc.). However, these descriptive terms remain high-yield for competitive exams.

Q: A 30-year-old woman, para 2, with hypertension presents with menorrhagia. What is the best treatment for her?

Mirena (Levonorgestrel-releasing intrauterine system). **Explanation:** The patient is a 30-year-old multiparous woman presenting with **menorrhagia** (Heavy Menstrual Bleeding) and a co-morbidity of **hypertension**. **Why Option B is Correct:** The **Mirena (LNG-IUS)** is the medical treatment of choice for menorrhagia. It works by releasing levonorgestrel directly into the uterine cavity, causing profound endometrial atrophy and reducing menstrual blood loss by up to 90-97%. In this specific case, Mirena is preferred over hormonal pills because the patient is **hypertensive**. Estrogen-containing contraceptives are generally avoided or used with caution in hypertension due to the risk of stroke and worsening blood pressure. Mirena provides effective local treatment without the systemic risks associated with estrogen. **Why Other Options are Incorrect:** * **Option A (COCPs):** Combined oral contraceptive pills contain estrogen, which is contraindicated in patients with uncontrolled hypertension or those with high cardiovascular risk. * **Option C (Hysterectomy):** This is a major surgical intervention. It is considered the definitive treatment but is reserved for cases where medical management fails or the patient has completed her family and specifically requests surgery. * **Option D (TCRE):** Endometrial ablation/resection is a second-line surgical alternative to hysterectomy. Medical management (Mirena) should always be attempted first in a 30-year-old. **NEET-PG High-Yield Pearls:** * **First-line medical management for HMB:** LNG-IUS (Mirena). * **Mechanism of Mirena:** Endometrial decidualization followed by atrophy. * **WHO Eligibility Criteria:** Estrogen is Category 3/4 for smokers >35 years and those with severe hypertension (BP >160/100). * **Non-hormonal first-line:** Tranexamic acid (Antifibrinolytic).

Q: What is typically observed in the uterine lining during the proliferative phase of the menstrual cycle?

Increased estrogen. **Explanation:** The menstrual cycle is divided into the ovarian cycle and the uterine cycle. The **proliferative phase** of the uterine cycle corresponds to the follicular phase of the ovarian cycle. **Why Option A is Correct:** During the early follicular phase, the rising levels of **Follicle Stimulating Hormone (FSH)** lead to the development of ovarian follicles. These follicles secrete increasing amounts of **estrogen** (primarily estradiol). Estrogen acts on the endometrium to stimulate mitotic activity, leading to the regeneration of the functional layer, thickening of the stroma, and elongation of the spiral arteries. Therefore, increased estrogen is the hallmark of this phase. **Why Other Options are Incorrect:** * **Options B & C:** Estrogen actually **upregulates** (increases) the expression of both estrogen receptors (ER) and progesterone receptors (PR) in the endometrial tissue. This "priming" effect is essential because it allows the endometrium to respond to progesterone during the subsequent secretory phase. * **Option D:** While the pituitary hormones (FSH/LH) drive the cycle, the term "imbalance" implies a pathological state (like PCOS or hyperprolactinemia). In a normal physiological proliferative phase, the pituitary hormones are in a coordinated, functional flux, not an imbalance. **NEET-PG High-Yield Pearls:** * **Histology:** The proliferative phase is characterized by **tubular, straight glands** and numerous mitotic figures. * **Dominant Hormone:** Estrogen (Proliferative phase); Progesterone (Secretory phase). * **Dating the Endometrium:** The most reliable sign of ovulation on an endometrial biopsy is **subnuclear vacuolation** (the earliest sign of the secretory phase). * **Triple Line Sign:** On ultrasound, the proliferative endometrium appears as a "triple-line" pattern.

Question 1

Secondary amenorrhea is defined as:

Accepted Answer

Absence of menstruation for three normal menstrual cycles.

Answer

Absence of menstruation for one normal menstrual cycle.

Answer

Absence of menstruation for six normal menstrual cycles.

Answer

Absence of menstruation for one year.

Question 2

What is the most common endometrial pattern in dysfunctional uterine bleeding?

Accepted Answer

Normal

Answer

Hyperplastic with Swiss-Cheese pattern

Answer

Nonsecretory

Answer

Atrophic

Question 3

What is the initial treatment of dysfunctional uterine bleeding in a young female?

Accepted Answer

Oral contraceptive pills

Answer

Danazol

Answer

Hysterectomy

Answer

Androgens

Question 4

Which of the following is NOT a treatment for dysfunctional uterine bleeding?

Accepted Answer

Ovariotomy

Answer

Oral contraceptive pills

Answer

Estrogen

Answer

Progesterone

Question 5

Which of the following is false regarding Mittelschmerz?

Accepted Answer

Treatment is with estrogen

Answer

Rarely lasts more than 12 hours

Answer

Spotting may be present

Answer

Usually occurs around the 14th day of the menstrual cycle

Question 6

In dysfunctional uterine bleeding (DUB), what is the typical hormonal imbalance?

Accepted Answer

Increased estrogen

Answer

Decreased progesterone receptors

Answer

Decreased estrogen receptors

Answer

Pituitary hormone imbalance

Question 7

A patient presents with a history of frequent cycles accompanied by heavy bleeding. What is this condition called?

Accepted Answer

Polymenorrhagia

Answer

Menorrhagia

Answer

Polymenorrhea

Answer

Metrorrhagia

Question 8

Bleeding associated with anovulation is due to which of the following?

Accepted Answer

Persistent proliferative endometrium.

Answer

Alterations in endometrial vascular structure.

Answer

Increased endometrial responsiveness to vasodilating prostaglandins.

Answer

Impaired prostaglandin concentration.

Question 9

A 30-year-old woman, para 2, with hypertension presents with menorrhagia. What is the best treatment for her?

Accepted Answer

Mirena (Levonorgestrel-releasing intrauterine system)

Answer

Combined oral contraceptive pills

Answer

Hysterectomy

Answer

Transcervical resection of the endometrium

Question 10

What is typically observed in the uterine lining during the proliferative phase of the menstrual cycle?

Accepted Answer

Increased estrogen

Answer

Decreased progesterone receptors

Answer

Decreased estrogen receptors

Answer

Pituitary imbalance of hormones

Menstrual Disorders — MCQs

Menstrual Disorders — MCQs

On this page

Practice by Chapter

Want unlimited practice?